{"id":71351,"date":"2026-07-23T12:30:36","date_gmt":"2026-07-23T10:30:36","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/07\/23\/kaempferols-potential-in-targeting-il-17-mediated-inflammatory-pathways-for-colorectal-cancer-treatment\/"},"modified":"2026-07-23T12:30:36","modified_gmt":"2026-07-23T10:30:36","slug":"kaempferols-potential-in-targeting-il-17-mediated-inflammatory-pathways-for-colorectal-cancer-treatment","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/07\/23\/kaempferols-potential-in-targeting-il-17-mediated-inflammatory-pathways-for-colorectal-cancer-treatment\/","title":{"rendered":"Kaempferol&#8217;s potential in targeting IL-17-mediated inflammatory pathways for colorectal cancer treatment"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2026 Jul 10;215(7):vkag176. doi: 10.1093\/jimmun\/vkag176.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Colorectal cancer (CRC) is a leading malignancy with limited treatment options at advanced stages. Interleukin (IL)-17 signaling promotes tumor progression and immune evasion. Kaempferol, a natural flavonol, has anti-inflammatory and antitumor effects, but its role in modulating IL-17 pathways in CRC is unclear. We used an immunocompetent MC38 xenograft model to evaluate kaempferol monotherapy (50\/100 mg\/kg), its combination with a PD-L1 inhibitor, and IL-17 overexpression. Tumor growth, immune infiltration, cytokines, and signaling pathways were assessed using immunohistochemistry, enzyme-linked immunosorbent assay, flow cytometry, and Western blotting. Kaempferol suppressed tumor growth in a dose-dependent manner and showed synergistic effects with PD-L1 inhibitors. It enhanced CD4+ and CD8+ T cell infiltration, reduced IL-17A+ \u03b3\u03b4 T cells, and increased IFN-\u03b3+ \u03b3\u03b4 T cells. Kaempferol also downregulated IL-6, tumor necrosis factor \u03b1, and IL-17A and upregulated IL-2 and interferon \u03b3. Molecular analyses showed inhibition of IL-17A, PD-L1, STAT3, and NF-\u03baB pathway activation. IL-17A overexpression reversed these effects, restoring inflammation, immune suppression, and tumor growth. Kaempferol inhibits CRC progression by targeting IL-17-mediated inflammation and improving antitumor immunity, especially when combined with PD-L1 inhibitors. This study supports kaempferol&#8217;s potential as a novel therapeutic strategy for CRC.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42486478\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20260723063036&amp;v=2.20.0\">42486478<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkag176\">10.1093\/jimmun\/vkag176<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2026 Jul 10;215(7):vkag176. doi: 10.1093\/jimmun\/vkag176. ABSTRACT Colorectal cancer (CRC) is a leading malignancy with limited treatment options at advanced stages. Interleukin (IL)-17 signaling promotes tumor progression and immune evasion. Kaempferol, a natural flavonol, has anti-inflammatory and antitumor effects, but its role in modulating IL-17 pathways in CRC is unclear. We used an immunocompetent &#8230; <a title=\"Kaempferol&#8217;s potential in targeting IL-17-mediated inflammatory pathways for colorectal cancer treatment\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/23\/kaempferols-potential-in-targeting-il-17-mediated-inflammatory-pathways-for-colorectal-cancer-treatment\/\" aria-label=\"Read more about Kaempferol&#8217;s potential in targeting IL-17-mediated inflammatory pathways for colorectal cancer treatment\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-71351","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/71351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=71351"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/71351\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=71351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=71351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=71351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}